Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$22.62
Change (%) Stock is Down 0.49 (2.12%)
Volume3,497,735
Data as of 02/22/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
02/17/17Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary TumorsPrinter Friendly Version
02/07/17Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15Printer Friendly Version
02/02/17Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017Printer Friendly Version
01/31/17Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Printer Friendly Version
Upcoming EventsMore >>
Q4 2016 Exelixis Inc. Financial Results Conference Call
Monday, February 27, 2017 5:00 p.m. ET
Add to Calendar Add Q4 2016 Exelixis Inc. Financial Results Conference Call    to Calendar  Help
remind me days before the event

Enter your e-mail address 
Featured Report
Download Documentation2015 Annual Report (pdf)
Download Documentation2014 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.